GUGGENHEIM CAPITAL LLC - GLOBAL BLOOD THERAPEUTICS IN ownership

GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 247 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q3 2022. The put-call ratio across all filers is 0.56 and the average weighting 0.6%.

Quarter-by-quarter ownership
GUGGENHEIM CAPITAL LLC ownership history of GLOBAL BLOOD THERAPEUTICS IN
ValueSharesWeighting
Q3 2022$1,916,000
+76.1%
28,129
-34.1%
0.02%
+157.1%
Q3 2021$1,088,000
-17.2%
42,692
+13.8%
0.01%
-12.5%
Q2 2021$1,314,000
-10.0%
37,522
+4.7%
0.01%
-20.0%
Q1 2021$1,460,000
-14.0%
35,824
-8.6%
0.01%
-9.1%
Q4 2020$1,698,000
-28.1%
39,198
-8.5%
0.01%
-35.3%
Q3 2020$2,362,000
-25.3%
42,840
-14.5%
0.02%
-29.2%
Q2 2020$3,164,000
+60.3%
50,114
+29.7%
0.02%
+20.0%
Q1 2020$1,974,000
-47.3%
38,633
-18.0%
0.02%
-28.6%
Q4 2019$3,745,000
+64.8%
47,117
+0.6%
0.03%
+55.6%
Q3 2019$2,273,000
-7.6%
46,839
+0.1%
0.02%
-10.0%
Q2 2019$2,461,000
-20.0%
46,796
-19.5%
0.02%
-20.0%
Q1 2019$3,075,000
+18.0%
58,105
-8.4%
0.02%
+13.6%
Q4 2018$2,605,000
+3.7%
63,468
-3.9%
0.02%
+37.5%
Q3 2018$2,511,000
-12.6%
66,077
+3.9%
0.02%
-15.8%
Q2 2018$2,874,000
+4.9%
63,571
+12.1%
0.02%
+171.4%
Q1 2018$2,740,000
+18.8%
56,721
-3.2%
0.01%
+40.0%
Q4 2017$2,307,000
-27.5%
58,599
-42.8%
0.01%
-28.6%
Q3 2017$3,182,000
+144.8%
102,485
+115.5%
0.01%
+133.3%
Q2 2017$1,300,00047,5470.00%
Other shareholders
GLOBAL BLOOD THERAPEUTICS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Logos Global Management LP 850,000$46,869,0006.00%
Asymmetry Capital Management, L.P. 155,232$8,559,0005.50%
Grace Capital 124,749$6,878,0005.33%
Fernwood Investment Management, LLC 187,477$10,337,0004.88%
Perceptive Advisors 5,800,996$319,867,0004.67%
ArchPoint Investors 217,510$11,993,0003.83%
GREAT POINT PARTNERS LLC 655,676$36,154,0003.25%
Profit Investment Management, LLC 42,196$2,328,0001.44%
Bain Capital Public Equity Management II, LLC 381,868$21,056,0001.39%
Taylor Wealth Management Partners 52,597$2,900,0001.33%
View complete list of GLOBAL BLOOD THERAPEUTICS IN shareholders